Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Down 7.18%
As of Friday, October 23, Scribe Therapeutics Inc.’s SCTX share price has dipped by 7.18%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Commentary & Analysis
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Down 7.90%
As of Thursday, October 22, Scribe Therapeutics Inc.’s SCTX share price has dipped by 7.90%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Up 7.74%
As of Tuesday, October 20, Scribe Therapeutics Inc.’s SCTX share price has surged by 7.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Up 9.83%
As of Wednesday, October 14, Scribe Therapeutics Inc.’s SCTX share price has surged by 9.83%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Scribe Therapeutics Inc.’s (SCTX) Stock Is Up 10.77%
As of Wednesday, October 14, Scribe Therapeutics Inc.’s SCTX share price has surged by 10.77%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $291.6 | $229.7 | 32% |
|
| Shares Out (Mil) | 2.5 | 53.4 | 9% |
|
| Institutional Ownership | 61.3% | 92.9% | 39% |
|
| Float (Mil) | 6.9 | 41.7 | 15% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 403 | 520 | 55% |
|
| Price Change (52-week) |
na | 46.5% | na |
|
| Growth | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($1.030) | ($5.590) | ($3.617) | |
| Month Ago EPS | ($1.030) | ($5.590) | ($3.617) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (60.6%) | (37.7%) | (50.4%) | |
| Financials | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $33 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($32) | ($44) | 20% |
|
| EPS (TTM) | ($13.176) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($38) | ($33) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $26 | $2 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $533 | $175 | 35% |
|
| Valuation | SCTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SCTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (53.3%) | 66.5% | 2% |
|
| Net Margin | (97.0%) | (75.9%) | 8% |
|
| ROA | (111.5%) | (47.2%) | 5% |
|
| ROE | 39.2% | (53.5%) | 91% |
|
| Liabilities to Assets | 176.8% | 29.4% | 98% |
|
| F-Score | 0 | 2 | na |
|
Scribe Therapeutics Inc. did not pass any screens on 10/23/2026.
